The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Gemcitabine Plus Vinorelbine Compared With Cisplatin Plus Vinorelbine or Cisplatin Plus Gemcitabine for Advanced Non–Small-Cell Lung Cancer: A Phase III Trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group
Abstract
Purpose: Platinum-containing chemotherapy regimens are the standard treatment for patients with advanced non–small-cell lung cancer (NSCLC), although toxicity is common and may significantly affect the patient’s quality of life (QoL). This trial aimed to assess whether a combination of gemcitabine and vinorelbine had benefits in terms of QoL, without influencing negatively on survival, compared with cisplatin-containing regimens. Patients and Methods: Patients with stage IIIB (effusion and supraclavicular nodes) or IV documented NSCLC who were younger than 70 years of age were randomly assigned gemcitabine plus vinorelbine (GemVin) or either gemcitabine plus cisplatin or vinorelbine plus cisplatin (cisplatin-based). European Organization for Research and Treatment of Cancer scales were used for QoL analysis. Results: Five hundred one patients were randomly assigned to treatment. The median age was 62 years. There were no significant differences in global QoL scores between the two arms after 2 months of treatment. However, worsening scores for appetite, vomiting, and alopecia were significantly more common in the cisplatin-based arm. Median survival was 38 v 32 weeks and median progression-free survival was 23 v 17 weeks in the cisplatin-based versus GemVin arms, respectively. For the GemVin arm the hazard ratio for death was 1.15 (90% confidence interval [CI], 0.96 to 1.37) and the hazard ratio for progression was 1.29 (90% CI, 1.10 to 1.52). Grade 3 or 4 myelosuppression, vomiting, alopecia, and ototoxicity were significantly more frequent with cisplatin-based treatment. Conclusion: Global QoL is not improved with GemVin, although advantages in some components of QoL were apparent. GemVin is less toxic than standard cisplatin-based chemotherapy. There is a nonsignificant slight survival advantage with cisplatin-based chemotherapy. GemVin could be offered to advanced NSCLC patients who express concern about toxicity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
Group sequential methods in the design and analysis of clinical trials
POCOCK, S. J. (1977) · Biometrika · doi:10.1093/biomet/64.2.191 · Cited by 1,831
Cited by
Azzoli, C. G., Baker, S., Temin, S., Pao, W., Aliff, T., Brahmer, J., Johnson, D. H., Laskin, J. L., Masters, G., Milton, D., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.23.5622 · Cited by 915
DNA Synthesis and Repair Genes RRM1 and ERCC1 in Lung Cancer
Zheng, Z., Chen, T., Li, X., Haura, E., Sharma, A., & Bepler, G. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065411 · Cited by 462
D'Addario, G., Pintilie, M., Leighl, N. B., Feld, R., Cerny, T., & Shepherd, F. A. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.045 · Cited by 363
Self-citationBepler, G., Kusmartseva, I., Sharma, S., Gautam, A., Cantor, A., Sharma, A., & Simon, G. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.1101 · Cited by 333
Bezjak, A., Tu, D., Seymour, L., Clark, G., Trajkovic, A., Zukin, M., Ayoub, J., Lago, S., de Albuquerque Ribeiro, R., Gerogianni, A., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.05.8073 · Cited by 296
Self-citation
Metadata
- Authors
- Gridelli, C., Gallo, C., Shepherd, F. A., Illiano, A., Piantedosi, F., Robbiati, S. F., Manzione, L., Barbera, S., Frontini, L., Veltri, E., Findlay, B., Cigolari, S., Myers, R., Ianniello, G. P., Gebbia, V., Gasparini, G., Fava, S., Hirsh, V., Bezjak, A., Seymour, L., & Perrone, F.
- Venue
- Journal of Clinical Oncology
- Published
- 2003-08-15
- Volume
- 21
- Issue
- 16
- Pages
- 3025-3034
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2154948351
- Cited by
- 247
- References
- 2
- FWCI
- 25.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.